

Abiraterone acetate for the treatment of metastatic castration-resistant prostate cancer not previously treated with chemotherapy

<http://guidance.nice.org.uk/TA/Wave27/8>

Dear Consultees and Commentators,

The manufacturer of abiraterone has informed us that they will not be able to make a submission for this appraisal.

The manufacturer stated that this is because it is necessary to incorporate evidence from a recently reported interim analysis into the modelling framework, that further primary research into utility evaluation and resource use in the specific population reflective of the license, and that new statistical frameworks need to be developed.

The manufacturer informed us that it is not possible to complete this work in a way to enable NICE to publish timely guidance. In line with our usual process, we will therefore suspend this appraisal. The manufacturer has notified us of their commitment to make a submission by then end of 2013. When the manufacturer notifies us that a submission can be provided this topic will be rescheduled into the appraisal programme as soon as possible. If you have sent us a statement, there will be an opportunity to revise it at that time.

If you wish to be kept informed about this appraisal, please complete the attached form and return it to us.

If you have any questions, please let me know.

Best wishes,

Jeremy

Jeremy Powell

Technology Appraisal Project Manager
National Institute for Health and Clinical Excellence
10 Spring Gardens | London SW1A 2BU | United Kingdom
Tel: 44 (0)20 7045 2248 | Fax: 44 (0)20 7061 9830

Web: <http://nice.org.uk>